Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC7401 in Heterozygous Familial Hypercholesterolemia
NCT07450378Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
01
Overview
A Phase 3 trial of rbd7022 in heterozygous familial hypercholesterolemia (HeFH), sponsored by Qilu Pharmaceutical. Planned start May 2026; status: not yet recruiting.
02
Drugs
rbd7022
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07450378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450378.